Safety and Effect on Memory of PYM50028 in Mild Alzheimer's Disease

Phase II Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Investigate the Safety, Effect on Cognition and Pharmacokinetic Profile of PYM50028 in Subjects With Mild Dementia of the Alzheimer's Type

The purpose of this study is to assess the effect of PYM50028 administered once daily for up to 12 weeks on the memory and other faculties of subjects with dementia due to Alzheimer's disease.

Inclusion Criteria:

• At least 50 years of age
• Diagnosis of possible or probable Alzheimer's disease
• Mini mental state examination score at least 16
• Good understanding of both written and verbal English
• A recent head scan that is consistent with the diagnosis of Alzheimer's disease

Exclusion Criteria:

• Recent history or clinical evidence of significant neurological disease other than dementia due to Alzheimer's disease
• Known to have another condition that is associated with dementia
• Use of psychotropic medication within the previous 4 weeks (excluding cholinesterase inhibitors, selective serotonin reuptake inhibitors and venlafaxine)
• Hormone replacement therapy started or changed within the previous 6 months
• Received any investigational drugs within the previous 12 weeks